
FDA granted Genentech priority review for its diabetic retinopathy treatment, Lucentis.

FDA granted Genentech priority review for its diabetic retinopathy treatment, Lucentis.

The National Institutes of Health announces grants for the development of strategies for the utilization of biomedical data sets.

New polymers from Dow presented at CPhI 2014 help maximize a pharmaceutical product's solubilization performance.

New investments, expansions, and company rebranding are discussed at CPhI.

Colorcon announced that it will cooperate with BASF to add Kollicoat IR immediate-release coating polymer to Colorcon's film-coating portfolio.

CPhI released Part 2 of its annual industry report focused on the future of the pharmaceutical industry.

West Pharmaceutical Services will be showcasing its portfolio of drug packaging and delivery system solutions at CPhI this year.

BD announces agreement to acquire CareFusion to further medication management and patient safety solutions.

Celebrating the best of pharma and recognizing companies that turn inspiration into innovation.

FDA outlines procedures for having a Critical Path Innovation Meeting with CDER.

This year's CPhI sees Molecular Profiles launching its ROADMAP to Clinical Trials screening platform.

FDA draft guidance outlines ways to minimize risk from acetaminophen-containing over-the-counter pediatric liquid drug products.

A change in the supply chain for three important Genentech cancer medications elicits a strong reaction from one of the nation?s largest operators of hospitals.

Almac expands its blister-packaging suite to meet the needs of two Japanese clients.

FDA releases question and answer draft guidance on drug product tracing and licensing requirements.

Norbrook Laboratories will be showcasing its portfolio of APIs and its range of Norbrook Finished Product at CPhI Worldwide 2014.

CPhI released Part 1 of its annual industry report focused on innovation in the market.

CPhI Worldwide 2014 brings new technology and expansions from Catalent.

Patheon will showcase its biologic, small molecule API development services, and manufacturing capabilities for finished dosage forms at CPhI/ICSE Worldwide.

New rules from the Treasury Department regarding inversion affect merger activity in the pharmaceutical sector.

The total market for biopharmaceuticals in 2013 was $36.8 billion according to Kalorama Information. Meanwhile, Frost & Sullivan estimates that the biosimilars market, which it pegged at just $1.2 billion in 2013, will grow to $23 billion in 2019, or more than 20-fold increase.

While advances in chemocatalysis for chiral synthesis continue apace, many companies have focused attention on the development of a wider array of enzymes that can be used under commercial manufacturing conditions for the selective conversion of various substrates into more complex intermediates.

Sigma-Aldrich has reached an acquisition agreement with Cell Marque to further their antibody portfolio.

Pharmaceutical Technology Europe spoke with Piero Iamartino, R&D director at Micro-Macinazione, about the role of micronization in pharmaceutical manufacturing.

The last 12 months have seen a number of major acquisitions in the contract manufacturing space.

Impurities, particulates, and a lack of communication are among Hospira's recent violations described in a warning letter from FDA.

Delivery of large protein biopharmaceuticals may now be administered orally with the help of microneedles, according to researchers at MIT.

Capsugel has received EXCiPACT certification for its sites in Bornem, Belgium, and Colmar, France.

Consort Medical announced that it has agreed terms to acquire the entire issued and to be issued share capital of Aesica Pharmaceuticals for £230 million.

LABOCHIM SpA completes construction on multipurpose high-potent API plant in Milan.